A carregar...
Does PRRT with standard activities of (177)Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocrine tumors
BACKGROUND: Peptide receptor radionuclide therapy (PRRT) with (177)Lu-[DOTA(0),Tyr(3)]octreotate ((177)Lu-octreotate) is generally performed using a fixed activity of 7.4 GBq (200 mCi) per course bound to 180 to 300 μg of the peptide. While this single activity may lead to suboptimal radiation doses...
Na minha lista:
| Main Authors: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3877953/ https://ncbi.nlm.nih.gov/pubmed/24369053 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2191-219X-3-82 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|